Laurel L Tangalakis1, Lawrence Tabone2, Anna Spagnoli3, Mike Muehlbauer4, Philip Omotosho3, Alfonso Torquati3. 1. Department of Surgery, Rush University Medical Center, 1750 W Harrison St, 791 Jelke, Chicago, IL, 60612, USA. laurel_l_tangalakis@rush.edu. 2. Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA. 3. Department of Surgery, Rush University Medical Center, 1750 W Harrison St, 791 Jelke, Chicago, IL, 60612, USA. 4. Sarah W. Steadman Nutrition and Metabolism Center, Duke University Medical Center, Durham, North Carolina, USA.
Abstract
INTRODUCTION: Roux-en-Y gastric bypass (RYGB) is a well-established treatment for morbid obesity and type 2 diabetes. The effects of RYGB on bone metabolism and bone health are largely unknown. OBJECTIVE: Determine the changes in osteoclast function and bone density 1 year after RYGB as compared with a control group undergoing a diabetes support and education program (DSE). DESIGN: A prospective cohort study with patients matched for weight and age assigned to RYGB or DSE. SETTING: Large academic institution. PATIENTS OR OTHER PARTICIPANTS: Patients with type 2 diabetes mellitus and morbid obesity (body mass index greater than 35 kg/m2). INTERVENTION: Subjects either received laparoscopic RYBG or DSE, which consisted of nutritional, exercise, and dietary counseling performed by a certified diabetic educator and a nutritionist three times over a year. MAIN OUTCOME MEASURE: Osteoclast activity, bone mineral density. RESULTS: One year after, intervention subjects undergoing RYGB have a 280% increase in osteoclast activity as compared with a 7.6% increase in the DSE control group (P < 0.001). Furthermore, there was a statistically significant increase in sclerostin levels in subjects undergoing RYGB compared with an increase in the control group. The total bone mineral density was statistically unchanged within 1 year of intervention in both groups. A statistically significant decrease in bone mineral density in the left ribs (decrease of 6.8%, P < 0.05) and lumbar spine (decrease of 4.0%, P < 0.05) was seen 1 year after RYGB. CONCLUSIONS: There is a significant increase in osteoclast activity observed 1 year after RYGB; the long-term clinical implications of this increased bone metabolism are unknown.
INTRODUCTION: Roux-en-Y gastric bypass (RYGB) is a well-established treatment for morbid obesity and type 2 diabetes. The effects of RYGB on bone metabolism and bone health are largely unknown. OBJECTIVE: Determine the changes in osteoclast function and bone density 1 year after RYGB as compared with a control group undergoing a diabetes support and education program (DSE). DESIGN: A prospective cohort study with patients matched for weight and age assigned to RYGB or DSE. SETTING: Large academic institution. PATIENTS OR OTHER PARTICIPANTS: Patients with type 2 diabetes mellitus and morbid obesity (body mass index greater than 35 kg/m2). INTERVENTION: Subjects either received laparoscopic RYBG or DSE, which consisted of nutritional, exercise, and dietary counseling performed by a certified diabetic educator and a nutritionist three times over a year. MAIN OUTCOME MEASURE: Osteoclast activity, bone mineral density. RESULTS: One year after, intervention subjects undergoing RYGB have a 280% increase in osteoclast activity as compared with a 7.6% increase in the DSE control group (P < 0.001). Furthermore, there was a statistically significant increase in sclerostin levels in subjects undergoing RYGB compared with an increase in the control group. The total bone mineral density was statistically unchanged within 1 year of intervention in both groups. A statistically significant decrease in bone mineral density in the left ribs (decrease of 6.8%, P < 0.05) and lumbar spine (decrease of 4.0%, P < 0.05) was seen 1 year after RYGB. CONCLUSIONS: There is a significant increase in osteoclast activity observed 1 year after RYGB; the long-term clinical implications of this increased bone metabolism are unknown.
Entities:
Keywords:
Bariatric surgery; Bone loss; Bone mineral density; Osteoclast; Roux-en-Y gastric bypass
Authors: H N Rosen; A C Moses; J Garber; I D Iloputaife; D S Ross; S L Lee; S L Greenspan Journal: Calcif Tissue Int Date: 2000-02 Impact factor: 4.333
Authors: Nuria Vilarrasa; Patricia San José; Isabel García; Carmen Gómez-Vaquero; Pilar Medina Miras; Amador G Ruiz de Gordejuela; Carles Masdevall; Jordi Pujol; Joan Soler; José Manuel Gómez Journal: Obes Surg Date: 2011-04 Impact factor: 4.129
Authors: Elaine W Yu; Mary L Bouxsein; Adam E Roy; Chantel Baldwin; Abby Cange; Robert M Neer; Lee M Kaplan; Joel S Finkelstein Journal: J Bone Miner Res Date: 2014-03 Impact factor: 6.741
Authors: Isabelle Piec; Christopher Washbourne; Jonathan Tang; Emily Fisher; Julie Greeves; Sarah Jackson; William D Fraser Journal: Calcif Tissue Int Date: 2016-01-09 Impact factor: 4.333
Authors: Fernando Guerrero-Pérez; Anna Casajoana; Carmen Gómez-Vaquero; Nuria Virgili; Rafael López-Urdiales; Laura Hernández-Montoliu; Jordi Pujol-Gebelli; Javier Osorio; Anna Prats; Anna Vidal-Alabró; Manuel Pérez-Maraver; Sonia Fernández-Veledo; Joan Vendrell; Nuria Vilarrasa Journal: J Clin Med Date: 2020-06-11 Impact factor: 4.241